A citation-based method for searching scientific literature

Arturo Cesaro, Vanessa Bianconi, Felice Gragnano, Elisabetta Moscarella, Fabio Fimiani, Emanuele Monda, Olga Scudiero, Giuseppe Limongelli, Matteo Pirro, Paolo Calabrò. Biofactors 2020
Times Cited: 30







List of co-cited articles
155 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina.
Chiara Caselli, Serena Del Turco, Rosetta Ragusa, Valentina Lorenzoni, Michiel De Graaf, Giuseppina Basta, Arthur Scholte, Raffaele De Caterina, Danilo Neglia. Cardiovasc Diabetol 2019
22
31

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
20

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
20

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
16

PCSK9: a key modulator of cardiovascular health.
Nabil G Seidah, Zuhier Awan, Michel Chrétien, Majambu Mbikay. Circ Res 2014
359
16

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Ahmed Zaid, Anna Roubtsova, Rachid Essalmani, Jadwiga Marcinkiewicz, Ann Chamberland, Josée Hamelin, Michel Tremblay, Hélène Jacques, Weijun Jin, Jean Davignon,[...]. Hepatology 2008
277
16

PCSK9 and inflammation: a review of experimental and clinical evidence.
Amir Abbas Momtazi-Borojeni, Sarvenaz Sabouri-Rad, Antonio M Gotto, Matteo Pirro, Maciej Banach, Zuhier Awan, George E Barreto, Amirhossein Sahebkar. Eur Heart J Cardiovasc Pharmacother 2019
47
16

PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.
Jin M Cheng, Rohit M Oemrawsingh, Hector M Garcia-Garcia, Eric Boersma, Robert-Jan van Geuns, Patrick W Serruys, Isabella Kardys, K Martijn Akkerhuis. Atherosclerosis 2016
92
13


Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
Paul M Ridker, Nader Rifai, Gary Bradwin, Lynda Rose. Eur Heart J 2016
63
13

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
Karin Leander, Anders Mälarstig, Ferdinand M Van't Hooft, Craig Hyde, Mai-Lis Hellénius, Jason S Troutt, Robert J Konrad, John Öhrvik, Anders Hamsten, Ulf de Faire. Circulation 2016
119
13

Prognostic value of PCSK9 levels in patients with acute coronary syndromes.
Baris Gencer, Fabrizio Montecucco, David Nanchen, Federico Carbone, Roland Klingenberg, Nicolas Vuilleumier, Soheila Aghlmandi, Dik Heg, Lorenz Räber, Reto Auer,[...]. Eur Heart J 2016
96
13

Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals.
Chiara Macchi, Nicola Ferri, Chiara Favero, Laura Cantone, Luisella Vigna, Angela C Pesatori, Maria G Lupo, Cesare R Sirtori, Alberto Corsini, Valentina Bollati,[...]. Eur J Prev Cardiol 2019
27
14

Decreased PCSK9 expression in human hepatocellular carcinoma.
Mamatha Bhat, Nicolas Skill, Victoria Marcus, Marc Deschenes, Xianming Tan, Jeanne Bouteaud, Sarita Negi, Zuhier Awan, Reid Aikin, Janet Kwan,[...]. BMC Gastroenterol 2015
32
13

PCSK9 induces a pro-inflammatory response in macrophages.
Chiara Ricci, Massimiliano Ruscica, Marina Camera, Laura Rossetti, Chiara Macchi, Alessandra Colciago, Ilaria Zanotti, Maria Giovanna Lupo, Maria Pia Adorni, Arrigo F G Cicero,[...]. Sci Rep 2018
98
13

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression.
Patrick Labonté, Syntia Begley, Carl Guévin, Marie-Claude Asselin, Nasha Nassoury, Gaétan Mayer, Annik Prat, Nabil G Seidah. Hepatology 2009
117
13

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Marianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, Delphine Allard, Khadija Ouguerram, Martine Devillers, Corinne Cruaud, Suzanne Benjannet, Louise Wickham, Danièle Erlich,[...]. Nat Genet 2003
13

Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies.
Arturo Cesaro, Alessandra Schiavo, Elisabetta Moscarella, Silvio Coletta, Matteo Conte, Felice Gragnano, Fabio Fimiani, Emanuele Monda, Martina Caiazza, Giuseppe Limongelli,[...]. J Cardiovasc Med (Hagerstown) 2021
27
14

Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk.
Arturo Cesaro, Felice Gragnano, Fabio Fimiani, Elisabetta Moscarella, Vincenzo Diana, Ivana Pariggiano, Claudia Concilio, Francesco Natale, Giuseppe Limongelli, Eduardo Bossone,[...]. Eur J Prev Cardiol 2020
18
22

Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact.
Chiara Macchi, Nicola Ferri, Cesare R Sirtori, Alberto Corsini, Maciej Banach, Massimiliano Ruscica. Am J Pathol 2021
24
16

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
10

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Stephen J Nicholls, Rishi Puri, Todd Anderson, Christie M Ballantyne, Leslie Cho, John J P Kastelein, Wolfgang Koenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang,[...]. JAMA 2016
515
10


Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Marc S Sabatine, Robert P Giugliano, Stephen D Wiviott, Frederick J Raal, Dirk J Blom, Jennifer Robinson, Christie M Ballantyne, Ransi Somaratne, Jason Legg, Scott M Wasserman,[...]. N Engl J Med 2015
10

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
Gissette Reyes-Soffer, Marianna Pavlyha, Colleen Ngai, Tiffany Thomas, Stephen Holleran, Rajasekhar Ramakrishnan, Wahida Karmally, Renu Nandakumar, Nelson Fontanez, Joseph Obunike,[...]. Circulation 2017
138
10

PCSK9 as a Positive Modulator of Platelet Activation.
Marina Camera, Laura Rossetti, Silvia S Barbieri, Ilaria Zanotti, Barbara Canciani, Daniela Trabattoni, Massimiliano Ruscica, Elena Tremoli, Nicola Ferri. J Am Coll Cardiol 2018
34
10

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
David Cunningham, Dennis E Danley, Kieran F Geoghegan, Matthew C Griffor, Julie L Hawkins, Timothy A Subashi, Alison H Varghese, Mark J Ammirati, Jeffrey S Culp, Lise R Hoth,[...]. Nat Struct Mol Biol 2007
316
10

The PCSK9 decade.
Gilles Lambert, Barbara Sjouke, Benjamin Choque, John J P Kastelein, G Kees Hovingh. J Lipid Res 2012
276
10

Cognitive Function in a Randomized Trial of Evolocumab.
Robert P Giugliano, Marc S Sabatine, Brian R Ott. N Engl J Med 2017
14
21

Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis.
Amir Abbas Momtazi-Borojeni, Mahmoud Reza Jaafari, Ali Badiee, Maciej Banach, Amirhossein Sahebkar. BMC Med 2019
22
13

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Christine Landlinger, Marianne G Pouwer, Claudia Juno, José W A van der Hoorn, Elsbet J Pieterman, J Wouter Jukema, Guenther Staffler, Hans M G Princen, Gergana Galabova. Eur Heart J 2017
120
10

Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.
Matteo Pirro, Vanessa Bianconi, Daniela Francisci, Elisabetta Schiaroli, Francesco Bagaglia, Amirhossein Sahebkar, Franco Baldelli. J Cell Mol Med 2017
12
25

Adipokines in Liver Cirrhosis.
Christa Buechler, Elisabeth M Haberl, Lisa Rein-Fischboeck, Charalampos Aslanidis. Int J Mol Sci 2017
36
10

Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
Maria R Emma, Lydia Giannitrapani, Daniela Cabibi, Rossana Porcasi, Gianni Pantuso, Giuseppa Augello, Rosaria V Giglio, Noemi Lo Re, Adele R Capitano, Giuseppe Montalto,[...]. Biochim Biophys Acta Mol Cell Biol Lipids 2020
9
33

Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease.
Valentin Schlegel, Theresa Treuner-Kaueroff, Daniel Seehofer, Thomas Berg, Susen Becker, Uta Ceglarek, Joachim Thiery, Thorsten Kaiser. PLoS One 2017
7
42

Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis.
Martine Paquette, Dany Gauthier, Ann Chamberland, Annik Prat, Emanuella De Lucia Rolfe, Jon J Rasmussen, Lydia Kaduka, Nabil G Seidah, Sophie Bernard, Dirk L Christensen,[...]. Clin Biochem 2020
12
25

PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions.
Mika Hilvo, Helena Simolin, Jari Metso, Maija Ruuth, Katariina Öörni, Matti Jauhiainen, Reijo Laaksonen, Amos Baruch. Atherosclerosis 2018
39
10

Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.
Gulam Hussain Syed, Huihui Tang, Mohsin Khan, Tarek Hassanein, Jingwen Liu, Aleem Siddiqui. J Virol 2014
64
10

PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease.
Ji Soo Lee, Partha Mukhopadhyay, Csaba Matyas, Eszter Trojnar, Janos Paloczi, Yuan Ru Yang, Brandon A Blank, Cody Savage, Alexander V Sorokin, Nehal N Mehta,[...]. Sci Rep 2019
28
10

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.
Jonathan Cohen, Alexander Pertsemlidis, Ingrid K Kotowski, Randall Graham, Christine Kim Garcia, Helen H Hobbs. Nat Genet 2005
899
10

Liver fat accumulation is associated with circulating PCSK9.
Massimiliano Ruscica, Nicola Ferri, Chiara Macchi, Marica Meroni, Claudia Lanti, Chiara Ricci, Marco Maggioni, Anna Ludovica Fracanzani, Sara Badiali, Silvia Fargion,[...]. Ann Med 2016
77
10


PCSK9 inhibition and inflammation: A narrative review.
Massimiliano Ruscica, Lale Tokgözoğlu, Alberto Corsini, Cesare R Sirtori. Atherosclerosis 2019
44
10

PCSK9: From Basic Science Discoveries to Clinical Trials.
Michael D Shapiro, Hagai Tavori, Sergio Fazio. Circ Res 2018
98
10

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
Aarti Ramanathan, Viktoria Gusarova, Neil Stahl, Anne Gurnett-Bander, Christos A Kyratsous. PLoS One 2016
20
15

PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma.
Silvano Fasolato, Sabrina Pigozzo, Patrizia Pontisso, Paolo Angeli, Massimiliano Ruscica, Edoardo Savarino, Sara De Martin, Maria Giovanna Lupo, Nicola Ferri. J Clin Med 2020
11
27

Lipid Lowering Therapy and Circulating PCSK9 Concentration.
Tsuyoshi Nozue. J Atheroscler Thromb 2017
52
10


Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.
Susanne Feder, Reiner Wiest, Thomas S Weiss, Charalampos Aslanidis, Doris Schacherer, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler. Lipids Health Dis 2021
6
50

Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.
Felice Gragnano, Francesco Natale, Claudia Concilio, Fabio Fimiani, Arturo Cesaro, Simona Sperlongano, Mario Crisci, Giuseppe Limongelli, Raffaele Calabrò, Mariagiovanna Russo,[...]. J Cardiovasc Med (Hagerstown) 2018
19
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.